Drug search by name

Tesamorelin Subcutaneous and Diabetes

Result of checking the interaction of drug Tesamorelin Subcutaneous and disease Diabetes for safety when used together.

Check result:

Tesamorelin Subcutaneous <> Diabetes

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of tesamorelin can result in glucose intolerance. Tesamorelin increases insulin-like growth factor-1 (IGF-1). It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment. Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes. Diabetes patients should be monitored for potential development or worsening of retinopathy. Care should be exercised when using this agent in patients with diabetes.

Tesamorelin Subcutaneous

Generic Name: tesamorelin

Brand Name: Egrifta

Synonyms: Tesamorelin

What is Tesamorelin Subcutaneous?